BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of ...
BioAtla (BCAB) has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share ...
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable licensePhase 1 initiation for ...
BioAtla, Inc. announced an agreement under which Inversagen AI, LLC, backed by GATC Health Corp and Alliance International Resources Corp., will invest a total of $40 million in a special purpose ...
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
Image source: The Motley Fool. Management confirmed pursuit of a major partnership transaction targeted for completion by year-end and disclosed recent FDA alignment on the phase three trial design ...
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE)-- BioAtla, Inc. (NASDAQ: BCAB or the "Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ...
BioAtla develops precision antibody therapies to treat solid tumors. Its central technology, known as Conditionally Active Biologic (CAB), designs antibodies that become active in the acidic ...
SAN DIEGO & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein ...
Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results